Psilocybin desynchronizes the human brain
Persistent reduction of hippocampal-default mode network connectivity may represent a neuroanatomical and mechanistic correlate of the proplasticity and therapeutic effects of psychedelics.
​
Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders
This comprehensive review takes a deep dive into the world of psychedelics, covering their historical use, safety profile, mechanisms of action, effects on perception, and potential therapeutic applications. The review offers a multifaceted exploration of psychedelics' intriguing history and promising future in the field of mental health.
​
Magnesium–Ibogaine Therapy in Veterans with Traumatic Brain Injuries
This study explored the combined effects of magnesium and ibogaine therapy in veterans with traumatic brain injuries. The findings suggested that this combination therapy significantly improved cognitive function, reduced symptoms of PTSD, and promoted neural regeneration, highlighting a novel approach to TBI treatment.
​
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
A Phase III $100M clinical trial showed that after treatment with MDMA-assisted therapy, 67% of veterans and female rape victims no longer had PTSD.
​
Psychedelics Reopen the Social Reward Learning Critical Period
Conducted by researchers at Johns Hopkins Medicine, the study found that different psychedelics such as MDMA, LSD, psilocybin, ibogaine, and ketamine reopen these critical periods for varying durations, from 48 hours to several weeks. These findings suggest that psychedelics could potentially be used to treat conditions like depression and PTSD by enhancing social learning and brain plasticity.
​
Psilocybin for treatment-resistant depression
This paper investigates the effects of psilocybin treatment on patients with treatment-resistant depression using functional MRI. It reveals changes in brain connectivity and blood flow that correlate with reduced depressive symptoms, suggesting a potential therapeutic mechanism.
​
Classical psychedelics for the treatment of depression and anxiety: A systematic review
This review explores the potential of psychedelic-assisted therapy, using substances like ayahuasca, psilocybin, and LSD, as a promising alternative for treatment-resistant depression and anxiety. Based on the analysis of seven studies involving 130 patients, these psychedelics consistently demonstrated immediate and significant antidepressant and antianxiety effects with good safety profiles.
​
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression.
​
Psychedelics as Medicines: An Emerging New Paradigm
This paper discusses the growing scientific interest in psychedelics like psilocybin and LSD, exploring their potential for treating anxiety, depression, addiction, and inflammatory diseases through unique brain network mechanisms, suggesting a novel approach to therapy.
​
This paper examines the effects of naturalistic psilocybin use outside of clinical research settings through a series of surveys. The study finds that psilocybin use is associated with lasting reductions in anxiety, depression, and alcohol misuse, as well as increased cognitive flexibility and well-being.
​
Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation
This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder.
​
Long-term Follow-up of Psilocybin-facilitated Smoking Cessation
At 12-month follow-up, 67% of participants were confirmed as smoking abstinent. At long-term follow-up, 60% of participants were confirmed as smoking abstinent. At 12-month follow-up 86.7% of participants rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives.
​
Psilocybin-Assisted Psychotherapy + Alcohol Use Disorder
This study is a randomized clinical trial where psilocybin was administered in combination with psychotherapy and produced robust decreases in percentage of heavy drinking days over and above those produced by active placebo and psychotherapy.
​
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
This study explores why psychedelics help brain cells grow and change. It focuses on the 5-HT2A receptor, showing that specific parts of this receptor inside cells play a vital role in these positive effects.
​
Therapeutic use of psilocybin: Practical considerations for dosing and administration
This article aims to provide health care professionals with an overview of practical considerations for psilocybin therapy, such as pharmacology, dosing, administration, safety, and interactions. It aims to enhance healthcare professionals' knowledge and comfort in discussing and advising patients on psilocybin therapy to ensure better patient care and safety.
​
Structure–activity relationships of serotonin 5-HT2A agonists
This article aims to provide health care professionals with an overview of practical considerations for psilocybin therapy, such as pharmacology, dosing, administration, safety, and interactions. It aims to enhance healthcare professionals' knowledge and comfort in discussing and advising patients on psilocybin therapy to ensure better patient care and safety.
​
Psychedelic Therapy + Cancer Patients
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety.
​